Emerald Health Pharmaceuticals (EHP) is developing new pharmaceutical drug candidates by enhancing the known benefits of cannabinoid interactions with the human endocannabinoid system (ECS) to positively impact several serious diseases, including neurodegenerative, autoimmune, inflammatory, metabolic, and fibrotic diseases. Starting from synthetically manufactured cannabinoids, we create new molecules which target the ECS and other relevant receptors that may provide valuable therapeutic benefits against diseases with unmet medical needs.
EHP’s scientists have rationally designed and chemically modified non-psychotropic cannabinoids to affect several validated biological targets and physiological pathways in the body. These targets and pathways have been validated by independent third-party research as being pertinent to the diseases targeted by EHP’s drug product candidates, and our drug candidates have been shown in validated animal disease models to achieve therapeutic benefits that exceed the capabilities of natural cannabinoids.
As new chemical entities (NCEs), EHP’s molecules are protected by 16 issued international patents and 22 pending patents, including composition of matter, covering 25 different molecules.
EHP’s approach is unique. To our knowledge, no other researchers have yet developed a molecule with the ability to target all of the receptors targeted by EHP’s molecules, which provides the opportunity for a more effective and efficient approach to treating a wide range of diseases.